Cardiovascular Medicine

Cardiovascular Medicine Faculty

R. David Anderson, M.D., F.A.C.C. R. David Anderson, M.D., F.A.C.C. FSCAI
Division of Cardiovascular Medicine
Associate Professor of Medicine
Director, Interventional Cardiology
Director of the Cardiac Catheterization Laboratory, Shands Hospital, Gainesville, Fl.

e-mail: david.anderson@medicine.ufl.edu

1600 SW Archer Road/Box 100277
Gainesville, FL  32610-0277
352-273-9076 / FAX 352-846-0314

Training:

Degree
Program
Institution Field/Specialty
BSME Stevens Institute of Technology Mechanical Engineering
MS with Thesis University of Pennsylvania Biochemistry
MD Johns Hopkins University School of Medicine  
Residency University of Maryland Hospital Internal Medicine
Chief Resident University of Maryland Hospital  
Fellowship Duke University Medical Center Cardiovascular Medicine

Academic Interests:

Dr. Anderson has continued interest and participation in clinical trials of device and drug development for acute coronary syndromes. Interests also include the application of advanced interventional techniques such as rotational atherectomy, distal protection, as well as thrombectomy to the treatment of coronary artery disease. Additionally his interests include the endovascular treatment of peripheral arterial disease. Dr. Anderson has participated in the design and execution of multiple clinical trials involving the use of angiogenesis growth factors in the treatment of peripheral arterial disease and is actively involved in clinical trials of stem cell therapy.  He is an active member of the American College of Cardiology, the Florida Chapter of the American College of Cardiology, and the Society of Coronary Angiography and Intervention.

Clinical Interests:

Interventional Cardiology, Peripheral vascular intervention, Percutaneous Treatment of Valvular Disease, Clinical Trials

Representative Publications:

  • Singh M, Reeder GS, Ohman EM, Mathew V, Hillegass WB, Anderson RD, Gallup DS, Garrett KN, Holmes DR. Does the presence of thrombus seen on a coronary angiogram affect outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. J Am Coll Cardiol 2001;38:624-630.
  • Lederman RJ, Medelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor – 2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 2002;359:2053-2058.
  • Anderson RD, White HD, Ohman EM, Wagner GS, et al. Predicting outcome after Thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO-III trial. Am Heart J 2002;144(1):81-8.
  • Grossman P, Anderson RD, et al. Day 180 Results from a phase II Multi-center, Double blind Placebo-controlled study of VLTS-589 for intermittent claudication in subjects with peripheral arterial disease. Abstract presentation at American Heart Association 2005.
  • Anderson RD, Sizemore BC, Barrow GM, Johnson BD, Merz CN, Sopko G, VonMering GO, Handberg EM, Nichols WW,Pepine CJ.  Pulse Pressure and Adverse Outcomes in Women:  A Report From the Women’s Ischemia Syndrome Evaluation (WISE).  Am J of Hypertension. 2008.
  • Anderson RD, Pepine CJ.  Gender difference in the treatment for acute myocardial infarction: bias or biology? Circulation 2007:115(7):823-6.
  • Garasic JM, Marin L, Anderson RD.  Acute Evaluation of the Mynx™ Vascular Closure Device During Arterial re-puncture in and Ovine Model.  Journal of Invasive Cardiology. J Invasive Cardiol 2009;21:283-285.

Visit Pubmed for full list of publications

Primary Navigation